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Abstract
AIM: To determine the possible modulating effect of 
the COX-2  polymorphisms, -765G→C and -1195A→G, 
on the risk of colorectal cancer (CRC) in a Dutch popu-
lation.
METHODS: This case-control study includes 326 pa-
tients with CRC and 369 age- and gender-matched 
controls. Genotypes of the COX-2  polymorphisms 
-765G→C and -1195A→G were determined by poly-
merase chain reaction-based restriction fragment 
length polymorphism. COX-2  genotypes and haplo-
types were analyzed and odds ratios with 95% confi-
dence intervals were estimated by logistic regression. 
RESULTS: The -765GG genotype was associated 
with an increased risk of developing CRC (OR, 1.45; 
95% CI, 1.03-2.04). No significant difference was 
observed in the genotype distribution of the -1195A→
G polymorphism between patients and controls. The 
GG/AC  haplotype was present significantly less often in 
patients than in controls (OR 0.44; 95% CI, 0.22-0.85). 
When the AC , AG and GG haplotypes were investigated 
separately, the AC  haplotype showed a tendency to be 
less frequent in patients than in controls (OR(AG/AC) 0.78; 
95% CI, 0.57-1.06).
CONCLUSION: The -765GG genotype is associated 
with an increased risk of developing CRC and the GG/
AC haplotype seems to protect against CRC. These 
findings suggest a modulating role for the COX-2  
polymorphisms -765G→C and -1195A→G in the 
development of CRC in a Dutch population. 
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
Colorectal cancer (CRC) is a common disease in both 
men and women. CRC includes cancerous growths in 
the cecum, colon, sigmoid and rectum. In Western coun-
tries, 5% of  the population ultimately develop CRC, thus 
this disease is an important public health issue[1]. CRC is 
ranked the third most common form of  cancer world-
wide in terms of  incidence[2]. In the Netherlands, CRC 
is the second most common form of  cancer affecting 
women and the third most common form of  cancer af-
fecting men. In 2003 in the Netherlands 9898 new cases 
of  CRC were diagnosed[3]. 
CRC is usually observed in one of  three specific pat-
terns: sporadic, inherited or familial. The sporadic form 
accounts for approximately 70% in the population and is 
most common in individuals older than 50 years of  age, 
probably as a result of  interactions between low pene-
trance genes and environmental factors. Fewer than 10% 
of  the population has an inherited predisposition to co-
lon cancer. Inherited colon cancer is usually the result of  
a single germ line mutation. The third pattern, familial 
colon cancer, includes those families in which CRC de-
velops too frequently to be considered as sporadic colon 
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cancer and which are not in a pattern consistent with an 
inherited syndrome. Up to 25% of  all cases of  CRC are 
estimated to fall into this category[1].
Cyclooxygenase (COX), also known as prostaglandin 
endoperoxidase H synthase, is a modifier gene and key 
enzyme in the conversion of  arachidonic acid into pros-
taglandins. 
The COX family consists of  two isozymes: COX-1 
and COX-2. COX-1 is constitutively expressed in most 
cell types and is involved in the homeostasis of  various 
physiological functions. COX-1 is well known as the 
housekeeping gene. COX-2 is an inducible form and 
its expression can be induced by mitogenic and proin-
flammatory stimuli. Increased expression of  COX-2 is 
observed in many types of  cancers. COX-2 is also as-
sociated with many stages of  cancer development, e.g. 
invasion, metastasis, hyperproliferation, transformation 
and tumor growth[4,5]. 
Recent studies suggest that single nucleotide poly-
morphisms (SNPs) in the COX-2 promoter may alter the 
enzyme function of  COX-2 by differential regulation 
of  COX-2 expression. A differential COX-2 expression 
may influence the risk of  the development of  gastroin-
testinal adenocarcinomas, including CRC[6-9].
In a study of  African-Americans, an inverse associa-
tion was found between the Val511Ala polymorphism 
and the risk of  CRC[8]. In two studies the promoter 
polymorphisms -765G→C and -1195A→G were associ-
ated with an increased risk of  CRC[9,10], whereas Ulrich 
et al[11] reported a reduced risk of  CRC associated with 
the -765G→C polymorphism. The inconsistent results 
may indicate that the COX-2 polymorphisms -765G→
C and -1195A→G may play a role in carcinogenic proc-
esses in combination with specific life-style conditions 
or dependent on the racial composition of  a particular 
population. 
The purpose of  our study was to determine the pos-
sible modulating effect of  the COX-2 polymorphisms 
-765G→C and -1195A→G on the risk of  sporadic CRC 
in a Dutch population. The results of  this research will 
lead to a better understanding on the role of  SNPs in 
the COX-2 promoter in colon cancer carcinogenesis. 
Such knowledge in future may eventually lead to better 
preventive measures for CRC.
MATERIALS AND METHODS
Patients and controls
This case-control study included 326 patients with CRC 
(59.8% men, 40.2% women) and 369 cancer-free con-
trols (59.1% men, 40.9% women). In the patient group, 
31.0% had a proximal tumor and 68.1% had a distal tu-
mor, whereas in 0.9% of  cases localization of  the tumor 
was unknown (see legend of  Table 1). All subjects were 
of  Caucasian origin with a mean age of  63.7 years and 
were recruited at Radboud University Nijmegen Medical 
Center, the Netherlands. The patient and control groups 
were matched for gender and age. The characteristics of  
patients and controls are summarized in Table 1. 
Genotyping
DNA from patients and controls was isolated from 
whole blood using the Pure Gene DNA isolation kit 
(Gentra Systems, Minneapolis, MN) and stored at 4℃. 
Genotypes of  the COX-2 -765G→C and -1195A→G 
polymorphisms were determined by polymerase chain 
reaction (PCR)-based restriction fragment length poly-
morphism, according to the method of  Zhang et al[5]. 
First, PCR was used to amplify the COX-2 pro-
moter region containing the polymorphism -765G
→C and -1195A→G . The pr imers used to am-




GCCCTTCATAGGAGATACTGG-3'. PCR was per-
formed using a 25 μL reaction mixture containing 100 ng 
of  DNA, 10 mmol/L of  Tris/HCl (pH 9.0), 50 mmol/L 
of  KCl, 0.1% of  Triton X-100, 2 mmol/L of  MgCl2, 200 
nmol/L of  each primer, 250 μmol/L of  deoxyribonucle-
otide triphosphates and 2.5 U Taq DNA polymerase. The 
PCR profile for the -1195A→G polymorphism consisted 
of  an initial melting step of  3 min at 95℃, followed by 
40 cycles of  30 s at 95℃, 30 s at 58℃, 30 s at 72℃ and a 
final elongation step of  7 min at 72℃. Cycle conditions 
for the -765G→C polymorphism were 4 min at 95℃, 
followed by 40 cycles of  30 s at 95℃, 30 s at 54℃, 30 s 
at 72℃ and finally the same elongation step as for the 
-1195A→G PCR assay. The samples were then analyzed 
by agarose gel electrophoresis for control of  the PCR 
products.
The PCR products (10 μL) were incubated with 
10 U of  restriction enzymes PvuⅡ and Hha1 at 37℃ 
for determination of  the -1195A→G and -765G→
C genotypes, respectively. Finally, the samples were 
analyzed by agarose gel electrophoresis. The -765G→C 
and -1195A→G genotypes that could be detected were: 
765CC (100 bp fragment), 765GC (100 + 74 + 26 bp 
fragments), 765GG (74 + 26 bp fragments), 1195AA (273 
bp fragment), 1195GA (273 + 220 + 53 bp fragments) 
and 1195GG (220 + 53 bp fragments), respectively.   
Statistical analysis
The data analysis was performed using SPSS software 
www.wjgnet.com
Table 1  Characteristics of patients with colorectal cancer 
(CRC) and controls (mean ± SD)
Patients with CRC 
(n  = 326)
Controls 
(n  = 369)
Age (yr)    62.7 ± 11.7    64.5 ± 10.7
Male gender 195 (59.8%) 218 (59.1%)
Female gender 131 (40.2%) 151 (40.9%)
Localization of tumor1
   Proximal2 101 (31.0%)
   Distal3 222 (68.1%)
1Note that the localization of the tumor was unknown in 3 patients; 
2Proximal tumor: cecum, ascending and transverse colon; 3Distal tumor: 
descending colon, sigmoid, rectosigmoid junction and rectum.
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(Version 14.0, SPSS, Chicago, IL, USA). Logistic 
regression was used to assess the association between the 
genotypes and the risk of  CRC. The statistical significance 
of  the -1195A→G and -765G→C genotype distributions 
between the patient and control groups was determined 
by Chi-square analysis. A P-value of  < 0.05 was used as 
the criterion of  statistical significance and all analyses were 
adjusted for age and sex. A test for deviation from the 
Hardy-Weinberg equilibrium, by comparing the expected 
to observed genotype frequencies, was used. Odds ratios 
(ORs) and 95% confidence intervals (CI) were calculated. 
Based on the two polymorphisms tested, a haplotype 
analysis was performed. In the two populations studied, 
seven different haplotypes could be distinguished: AC/
AC, AG/AC, AG/AG, GC/AC, GG/AC, GG/AG 
and GG/GG. The localization of  the tumor, distal or 
proximal, was also included in the database analyses.
RESULTS
Using cancer-free controls as a reference we tested 
for an association of  the two COX-2 polymorphisms 
with CRC. The genotype distributions in patients and 
controls of  the two COX-2 polymorphisms investigated 
are summarized in Table 2. The observed genotype 
distr ibutions for the -765G→C and -1195A→G 
polymorphisms in patients with CRC and controls were 
in accordance with the Hardy-Weinberg equilibrium, 
with P-values of  0.19 and 0.99 for patients with CRC 
and 0.24 and 0.46 for controls, respectively. When both 
polymorphisms were investigated separately, there was 
no significant difference in the -765G→C or -1195A→G 
allele frequency between the patient and control group. 
However, the -765GG genotype was more frequent in 
patients than in controls (OR, 1.45; 95% CI, 1.03-2.04). 
There was no significant difference in the genotype 
distribution of  the -1195A→G polymorphism among 
patients and controls.
Next , the potent ia l associat ion of  genotype 
distribution of  the two COX-2 polymorphisms with 
tumor localization was investigated. We distinguished 
proximal and distal tumor localization. Proximal included 
the cecum, colon ascendens and colon transversum and 
distal included the rectum, sigmoid, colon descendens 
and flexura lienalis. No association between the -765G
→C and -1195A→G polymorphisms and tumor 
localization was detected. 
Also no association of  the genotype distribution of  
the -765G→C and -1195A→G polymorphisms in the 
patient group was found with gender and age. 
Based on the two polymorphisms tested, a haplotype 
analysis was performed in the two populations studied 
and seven haplotypes could be distinguished (Table 3). 
A significant difference between the COX-2 haplotypes 
was observed. The GG/AC haplotype was less frequent 
in patients (OR, 0.44; 95% CI, 0.22-0.85). When the AC, 
AG and GG haplotypes were investigated separately; the 
AC haplotype tended to occur less frequently in patients 
than in controls (OR(AG/AC) 0.78; 95% CI, 0.57-1.06).
DISCUSSION
The COX-2 protein was detected in 70% of  all color-
ectal cancer tissues. In adjacent normal colorectal tissue 
in the same slide the COX-2 protein was not observed. 
These results suggest that increased expression of  
COX-2 is associated with CRC[12]. SNPs in the COX-2 
promoter may alter the enzyme activity of  COX-2 by 
differential regulation of  COX-2 expression, which may 
influence the risk of  the development of  CRC[7-9]. It has 
been recently demonstrated that the polymorphisms 
-765G→C and -1195A→G may have a functional effect 
on COX-2 expression and enzyme activity[7-9]. Both the 
-765G→C and -1195A→G polymorphisms were shown 
to display a lower COX-2 promoter activity, which may 
result in a lower expression of  the COX-2 enzyme[5,13].
We investigated the potential association of  the 
COX-2 polymorphisms -765G→C and -1195A→G and 
the risk of  developing CRC, and found that the -765GG 
genotype was present more often in patients than in con-
trols. As demonstrated by Zhang et al[5] the reporter gene 
expression driven by the -765G-containing COX-2 pro-
moter was higher as compared to the -765C-containing 
counterpart. This indeed could mean a higher COX-2 
expression in -765GG individuals.
A study in American Caucasians reported a reduced 
risk of  colorectal adenomas in individuals bearing the 
-765GG genotype, but this lower risk was found only 
among users of  non-steroidal antiinflammatory drugs 
(NSAIDs). In addition, a lower risk of  adenoma among 
-765CC genotypes was found only in non-users of  
NSAIDs[11]. Zhang et al[5] and Tan et al[9] reported that 
the -765GC genotype was associated with an increased 
www.wjgnet.com
Table 2  Genotype distribution and OR of the COX-2 
-1195A→G and -765G→C polymorphisms in patients with 
CRC and controls
Genotype Patients with CRC
(n  = 326)
Controls 
(n  = 369)
OR (95% CI)
     
-1195AA 213 (65.3%) 232 (62.9%) Reference
-1195GA 101 (31.0%) 124 (33.6%) 0.90 (0.66-1.23)
-1195GG 12 (3.7%) 13 (3.5%) 1.01 (0.45-2.25)
 -765GG 241 (73.9%) 249 (67.5%) Reference           
 -765GC      75 (23.0%) 112 (30.4%) 0.69 (0.49-0.97)
 -765CC 10 (3.1%)   8 (2.2%) 1.29 (0.50-3.33)
OR: Odds ratio; CI: Confidence interval.
Table 3  COX-2  haplotypes in patients with CRC and 
controls
Haplotype Patients with CRC 
(n  = 326)
Controls 
(n  = 369)
OR (95% CI)
AC/AC   9 (2.8%)   8 (2.2%)   1.16 (0.40-3.42)
AG/AC   59 (18.1%)   74 (20.1%) 0.83 (0.54-1.27)
AG/AG 145 (44.5%) 150 (40.7%) Reference
GC/AC   1 (0.3%)           -               -
GG/AC 16 (4.9%)   38 (10.3%) 0.44 (0.22-0.85)
GG/AG   84 (25.8%)    86 (23.3%) 1.01 (0.68-1.50)
GG/GG 12 (3.7%) 13 (3.5%) 0.92 (0.38-2.24)
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risk of  esophageal squamous cell carcinoma (ESCC) 
and CRC, in Chinese populations. The findings of  Tan 
et al[9] and Zhang et al[5] seem in contrast with our results, 
since we found a reduced risk of  CRC with the -765GC 
genotype. However, racial differences in the study popu-
lations may explain these apparent contradictory results, 
since the distribution of  the COX-2 polymorphisms 
studied here differs considerably between the Chinese 
and Dutch study populations. The genotype frequencies 
found in our Dutch patients with CRC for the -765G
→C and -1195A→G polymorphisms were: 73.9% GG, 
23.0% GC, 3.1% CC and 65.3% AA, 31.0% GA, 3.7% 
GG, respectively. Zhang et al[5] in a Chinese population 
reported genotype frequencies of  90.6% GG, 9.4% GC, 
0% CC and 30.5% AA, 52.9% GA and 16.6% GG. Tan 
et al[9] in Chinese patients with CRC recently reported 
approximately the same genotype frequencies as Zhang 
et al[5]: 91.6% GG, 8.4% GC, 0% CC and 34.5% AA, 
49.4% GA and 16.1% GG. These findings suggest that 
ethnic differences in genotype frequencies of  COX-2 
polymorphisms may have a significantly different modu-
lating effect on disease phenotypes in different ethnic 
populations.   
According to Zhang et al[5] and Tan et al[9] in a Chi-
nese population, the -1195GA and -1195AA genotypes 
were associated with an increased risk of  ESCC and 
CRC, respectively. This again is not in line with our 
findings, since we could not demonstrate a significant 
difference in the allele distribution of  the -1195A→G 
polymorphism between our Dutch patients with CRC 
and controls.
We also investigated the potential association of  the 
genotype distributions of  the -1195A→G and -765G→C 
polymorphisms with tumor localization. No association 
between the two polymorphisms and tumor localization 
was found, which is in accordance with the results of  
Tan et al[9] who found a very similar distribution of  both 
COX-2 genotypes in patients with colon (n = 403) or 
rectal (n = 597) cancer. 
The COX-2 GG/AC haplotype (-1195G-765G/-
1195A-765C) was found to be present less frequently in 
patients. When the AC, AG and GG haplotypes were 
investigated separately, the AC haplotype tended to be less 
frequently present in patients with CRC than in controls 
(OR(AG/AC) 0.78; 95% CI, 0.57-1.06). This is in line with the 
findings of  Zhang et al[5] who demonstrated that the lucif-
erase expression of  the AG constructs was higher than the 
expression of  the AC constructs, suggesting that the AC 
haplotype was associated with a lower COX-2 expression 
and a decreased risk of  CRC.  
However, Zhang et al [5], Tan et al [9] and Moons 
et al[14] found an association of  the AC haplotype with an 
increased risk of  ESCC, CRC and esophageal adenocar-
cinoma (EAC). These findings are in contrast with our 
results, as described above. In addition, the predicted ex-
pression levels of  the COX-2 protein are higher in AG 
versus AC haplotype individuals, according to Zhang 
et al[5], which is not in agreement with the hypothesis that 
high expression of  COX-2 is a risk factor for colorectal 
or esophageal carcinoma. It should be noted however 
that haplotype frequencies of  AC are very low in the 
patient and control populations studied by Zhang et al[5] 
and Tan et al[9], being 4.5% vs 1.6% and 3.8% vs 1.8%, re-
spectively, compared to 21.2% vs 32.6% in our study. In 
the study of  Moons et al[14] the AC haplotype occurred in 
25.0% of  the total study population, who were patients 
with esophageal adenocarcinoma, Barrett’s esophagus 
and reflux esophagitis, a proportion which is very close 
to our data. In the study of  Moons et al[14] unfortunately 
no cancer-free controls were included, but patients with 
Barrett’s esophagus or reflux esophagitis were used as 
controls, both of  which would confer a risk of  esopha-
geal adenocarcinoma. 
In summary, we found a significant difference in 
the -765G→C polymorphism distribution between the 
patients with CRC and the control group; the -765GG 
genotype was associated with an increased risk for CRC. 
The GG/AC haplotype was found less frequently in 
patients with CRC and may be associated with a reduced 
risk of  CRC. These findings suggest a modulating role 
for the COX-2 polymorphisms -1195A→G and -765G
→C in the development of  CRC in a Dutch population.
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